{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:34:11Z","timestamp":1789263251455,"version":"build-2803163510"},"reference-count":49,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,6,7]],"date-time":"2010-06-07T00:00:00Z","timestamp":1275868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objectives:\u2002<\/jats:bold> The aim of the study was to investigate the effect of bortezomib on osteoblast proliferation and differentiation, as well as on bone matrix deposition for the first time in bisphosphonate\u2010na\u00efve, previously untreated patients with myeloma.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Twenty newly diagnosed patients received four cycles of bortezomib treatment, initially as monotherapy and then combined with a glucocorticoid from cycle two to four. Bone remodeling markers were monitored closely during treatment. Furthermore, the effects of bortezomib and a glucocorticoid on immature and mature osteoblasts were also studied <jats:italic>in vitro<\/jats:italic>.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Treatment with bortezomib caused a significant increase in bone\u2010specific alkaline phosphatase and pro\u2010collagen type I N\u2010terminal propeptide, a novel bone formation marker. The addition of a glucocorticoid resulted in a transient decrease in collagen deposition. <jats:italic>In vitro<\/jats:italic> bortezomib induced osteoblast proliferation and differentiation. Differentiation but not proliferation was inhibited by glucocorticoid treatment.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Bortezomib used as first\u2010line treatment significantly increased collagen deposition in patients with multiple myeloma and osteolytic lesions, but the addition of a glucocorticoid to the treatment transiently inhibited the positive effect of bortezomib, suggesting that bortezomib may result in better healing of osteolytic lesions when used without glucocorticoids in patients that have obtained remission with a previous therapy. The potential bone\u2010healing properties of single\u2010agent bortezomib are currently being explored in a clinical study in patients who have undergone high\u2010dose therapy and autologous stem cell transplantation.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2010.01485.x","type":"journal-article","created":{"date-parts":[[2010,6,7]],"date-time":"2010-06-07T15:25:13Z","timestamp":1275924313000},"page":"290-299","source":"Crossref","is-referenced-by-count":46,"title":["First\u2010line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation <i>in vitro<\/i>"],"prefix":"10.1111","volume":"85","author":[{"given":"Thomas","family":"Lund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"S\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Garnero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per T.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Ormstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Marie","family":"Delaiss\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Plesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_2_7_3_2","first-page":"5438","article-title":"Receptor activator of nuclear factor\u2010kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia AN","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3527"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.5.1953"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.201394498"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01193.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200564"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4986"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4940"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-034884"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030847"},{"key":"e_1_2_7_13_2","first-page":"394","article-title":"Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients","volume":"86","author":"Corso A","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05084.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.8.1047"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1997.12.6.869"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.11.168"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340802"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.593"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.065005331.x"},{"key":"e_1_2_7_21_2","first-page":"300","article-title":"Myeloma and bone disease: \u201cthe dangerous tango\u201d","volume":"4","author":"Epstein J","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05733.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00692.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.07030"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06356.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16198"},{"key":"e_1_2_7_27_2","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee S","year":"2008","journal-title":"J Clin Invest"},{"key":"e_1_2_7_28_2","first-page":"129","article-title":"Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation","volume":"33","author":"Munemasa S","year":"2008","journal-title":"Int J Oncol"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06829.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21310"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174300"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-059188"},{"key":"e_1_2_7_33_2","first-page":"929","article-title":"Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and\/or refractory multiple myeloma with less than optimal response to bortezomib alone","volume":"91","author":"Jagannath S","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07409.x"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.n.011"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.20463"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.07.112"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/107632701753337681"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.02.019"},{"issue":"14","key":"e_1_2_7_41_2","first-page":"14","article-title":"Pharmacology, pharmacokinetics, and practical applications of bortezomib","volume":"18","author":"Schwartz R","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07980.x"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2001.49177.x"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010011209064"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(96)00134-8"},{"key":"e_1_2_7_46_2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood.V75.3.715.715","article-title":"Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin\u20101 beta osteoclast activating factor\u2010induced bone resorption","volume":"75","author":"Ishikawa H","year":"1990","journal-title":"Blood"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1997.0209"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(02)00687-7"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(01)00422-7"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01164.x"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01485.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2010.01485.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:24:54Z","timestamp":1697419494000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01485.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,7]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1600-0609.2010.01485.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01485.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,7]]}}}